Establish the Development Center of Excellence (COE) to help address the industry-wide challenge of a drug development process that is increasingly complex, slow and expensive. The Development COE will distinguish Lilly from its peers by using one common operating system, one common set of priorities and a singular focus to streamline the development of new medicines. The ultimate goal of the Development COE is to accelerate the launch of important Lilly molecules over the next decade and bring innovative medicines to patients sooner.
Organize the company around five global business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health, thereby moving from a predominantly functionally-oriented organization to a business-unit structure.
Streamline the organization and align corporate and general and administrative functions to support the business with a focus on improved quality, strong customer service and reduced costs.
Reduce the company's cost structure by $1 billion and lower global headcount to 35,000 by the end of 2011, excluding strategic sales additions in high-growth emerging markets and Japan.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.